RE:RE:RE:TWO STUDIES: GO !We knew the oncology will be accepted they main thing is NASH although delayed by one quarter due to addressing some details wil be phase 3 and not phase 2b/3 which is important due to duration and costs of the program will be feasible.
The increased sakes despite many jurisdictions are in lockdown due to pandemic is impressive not to mention European sales will kick in late 2021.
But I think we should be quite pleased so at least they will be finalizing straight phase 3 NASH rescheduled from Q2 to Q3.
FredTheVoice wrote: Should we get use to that ? Onless we prefer one good news and the stock is down !!!!!
The company is now trying a different strategy.......three excellent news......
Lets see the market reaction.......
But I am sure that the path is clear for NEW INVESTORS TO BE VERY VERY CONFIDENT ABOUT THE FUTURE......
Even Analia......
GLTA
FTV.